Standard Care and the Path to Recovery
At a Glance
Alcoholic cardiomyopathy can improve when a person stops drinking completely and receives guideline-directed heart-failure treatment. Doctors may add thiamine when deficiency is a concern and reassess heart function after about 3 to 6 months before considering devices.
The treatment for alcoholic cardiomyopathy (ACM) is built on two essential goals: removing the toxic stressor (alcohol) and supporting the heart muscle with modern medications. When these two pillars are combined, many patients see a significant improvement in their heart’s ability to pump [1][2].
The Ultimate Disease Modifier: Abstinence
Complete abstinence from alcohol is considered the single most important step in treating ACM [2]. Unlike some other forms of heart failure, ACM is uniquely potentially reversible. Research shows that patients who stop drinking entirely often experience substantial recovery in their Left Ventricular Ejection Fraction (LVEF)—the measurement of how much blood your heart pumps out with each beat [1]. In contrast, continuing to drink heavily prevents the heart from healing and significantly increases the risk of hospitalization or death [3].
The Four Pillars of Medical Therapy
Because ACM causes your heart to become weak and enlarged (a condition called Heart Failure with Reduced Ejection Fraction or HFrEF), doctors use a standardized approach called Guideline-Directed Medical Therapy (GDMT) [2][4]. This “four-pillar” approach uses different classes of drugs that work together to reduce the workload on your heart and help it reshape itself.
Never start, combine, or stop these medicines without the prescribing team. They are titrated according to blood pressure, kidney function, potassium, volume status, rhythm, and other conditions.
- ARNI, ACE Inhibitor, or ARB: These are alternatives to one another. Medications such as sacubitril/valsartan (ARNI) help relax your blood vessels and reduce the hormones that cause heart scarring. Important: ACE inhibitors must not be taken together with sacubitril/valsartan and require an appropriate washout when switching [4][5].
- Beta-blockers: Drugs like carvedilol or metoprolol succinate slow your heart rate and protect the heart muscle from adrenaline. They are generally started or increased gradually when acute congestion is controlled [4].
- Mineralocorticoid Receptor Antagonists (MRAs): Medications like spironolactone or eplerenone help prevent the heart from becoming stiff and scarred, but they can cause dangerous hyperkalemia (high potassium) or kidney-function changes [4].
- SGLT2 Inhibitors: Drugs like dapagliflozin or empagliflozin have been found to significantly improve survival. They can contribute to dehydration and genital infections and have illness-related precautions [4][6].
In addition to these pillars, you may be prescribed loop diuretics (like furosemide). They relieve congestion but do not replace disease-modifying therapy or necessarily improve survival [7].
Medication Safety & Monitoring
- ARNI/ACE/ARB: Monitor BP and kidney function. Report dizziness/fainting or swelling of the face/throat.
- Beta-blockers: Monitor heart rate. Report unusual fatigue or worsening shortness of breath during titration.
- MRAs: Monitor potassium. Report muscle cramps/weakness.
- SGLT2i: Monitor hydration. Report severe genital infection symptoms or marked reduction in urination.
Nutritional Support: Thiamine (Vitamin B1)
Alcohol can interfere with how your body absorbs vitamins, particularly thiamine (Vitamin B1). A severe lack of thiamine can cause its own type of heart failure, sometimes called “wet beriberi” [8]. If your doctor suspects a deficiency or if you are at risk of malnourishment, they may prescribe thiamine supplements to ensure your heart has the nutrients it needs to function [9][10].
Device Therapies and Timelines
If your heart’s pumping ability remains low despite several months of complete abstinence and optimal medication, your doctor may discuss specialized heart devices [11][12]. These decisions are individualized and depend on optimized GDMT, duration of reduced EF, symptoms, rhythm, QRS duration/morphology, comorbidities, and expected survival:
- ICD (Implantable Cardioverter Defibrillator): A small device that monitors your heart rhythm and can deliver a “shock” if it detects a life-threatening, irregular heartbeat [13].
- CRT (Cardiac Resynchronization Therapy): A specialized pacemaker that helps the left and right sides of your heart beat in perfect sync, depending on specific ECG findings like QRS duration [14].
Most guidelines recommend reassessing after roughly 3 to 6 months of optimized therapy before deciding on these devices, as your heart may recover enough during this window [11][12]. During this waiting period, a “LifeVest”—a wearable cardioverter-defibrillator (WCD)—may be considered only for selected patients rather than routinely [15].
Common questions in this guide
What is the most important treatment for alcoholic cardiomyopathy?
What medications are used to treat alcoholic cardiomyopathy?
Could thiamine help if I have alcoholic cardiomyopathy?
Can heart function recover from alcoholic cardiomyopathy?
When might I need an ICD or CRT device?
What should I monitor while taking treatment for alcoholic cardiomyopathy?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What are the target doses for my four main heart failure medications, and how often will we adjust them?
- 2.Is it safe for me to start all four pillars of medication now, or do we need to stagger them based on my blood pressure or kidney function?
- 3.Given my history of alcohol use, should I be taking thiamine (Vitamin B1) as part of my recovery plan?
- 4.When will we repeat my echocardiogram to see if my heart function is improving with treatment and abstinence?
- 5.If my ejection fraction doesn't improve after several months, will I need a device like an ICD or CRT?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (15)
- 1
Prognostic Impact and Predictors of Ejection Fraction Recovery in Patients With Alcoholic Cardiomyopathy.
Amor-Salamanca A, Guzzo-Merello G, González-López E, et al.
Revista espanola de cardiologia (English ed.) 2018; (71(8)):612-619 doi:10.1016/j.rec.2017.11.032.
PMID: 29650446 - 2
Alcoholic cardiomyopathy: an update.
Domínguez F, Adler E, García-Pavía P
European heart journal 2024; (45(26)):2294-2305 doi:10.1093/eurheartj/ehae362.
PMID: 38848133 - 3
Malignant ventricular arrhythmias in alcoholic cardiomyopathy.
Guzzo-Merello G, Dominguez F, González-López E, et al.
International journal of cardiology 2015; (199()):99-105.
PMID: 26188828 - 4
Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy.
Malgie J, Clephas PRD, Brunner-La Rocca HP, et al.
Heart failure reviews 2023; (28(5)):1221-1234 doi:10.1007/s10741-023-10325-2.
PMID: 37311917 - 5
Improving the Management of Patients with Heart Failure with Reduced Ejection Fraction in Clinical Practice: The Case for Angiotensin Receptor-Neprilysin Inhibitor.
Iacoviello M, Maria Sarullo F, Bilato C, et al.
Cardiac failure review 2025; (11()):e16 doi:10.15420/cfr.2024.39.
PMID: 40741340 - 6
Guidelines for treating heart failure.
Kittleson MM
Trends in cardiovascular medicine 2025; (35(3)):141-150 doi:10.1016/j.tcm.2024.10.002.
PMID: 39442740 - 7
Heart failure with reduced ejection fraction.
Cannata A, Crespo-Leiro MG, Bromage DI, et al.
Lancet (London, England) 2026; (407(10527)):529-542 doi:10.1016/S0140-6736(25)01851-3.
PMID: 41319669 - 8
Thiamine responsive high output heart failure of adults: an under-recognized entity.
Nisar S, Mohi-U-Din K, Tak SI, et al.
European journal of clinical nutrition 2023; (77(7)):757-760 doi:10.1038/s41430-023-01279-7.
PMID: 36859659 - 9
Low rates of thiamine prescribing in adult patients with alcohol-related diagnoses in the emergency department.
Peck NM, Bania TC, Chu J
The American journal of drug and alcohol abuse 2021; (47(6)):704-710 doi:10.1080/00952990.2021.1889575.
PMID: 33780650 - 10
Thiamine mediated reversal of left ventricular dysfunction in patients with alcoholic cardiomyopathy.
Satish OS, Shaik SA
Indian heart journal 2021; (73(3)):389-391 doi:10.1016/j.ihj.2021.03.013.
PMID: 34154766 - 11
Early Implantation of Primary Prevention Implantable Cardioverter Defibrillators for Patients with Newly Diagnosed Severe Nonischemic Cardiomyopathy.
Voskoboinik A, Bloom J, Taylor A, Mariani J
Pacing and clinical electrophysiology : PACE 2016; (39(9)):992-8 doi:10.1111/pace.12911.
PMID: 27343008 - 12
New-onset left bundle branch block-associated idiopathic nonischemic cardiomyopathy and left ventricular ejection fraction response to guideline-directed therapies: The NEOLITH study.
Wang NC, Singh M, Adelstein EC, et al.
Heart rhythm 2016; (13(4)):933-42.
PMID: 26688064 - 13
Distribution of Ventricular Fibrosis Associated With Life-Threatening Ventricular Tachyarrhythmias in Patients With Nonischemic Dilated Cardiomyopathy.
Chimura M, Kiuchi K, Okajima K, et al.
Journal of cardiovascular electrophysiology 2015; (26(11)):1239-1246 doi:10.1111/jce.12767.
PMID: 26223827 - 14
Defibrillators: Selecting the Right Device for the Right Patient.
Al-Khatib SM, Friedman P, Ellenbogen KA
Circulation 2016; (134(18)):1390-1404 doi:10.1161/CIRCULATIONAHA.116.021889.
PMID: 27799257 - 15
Ventricular arrhythmias in patients with newly diagnosed nonischemic cardiomyopathy: Insights from the PROLONG study.
Duncker D, König T, Hohmann S, et al.
Clinical cardiology 2017; (40(8)):586-590 doi:10.1002/clc.22706.
PMID: 28333373
This page explains treatment and recovery planning for alcoholic cardiomyopathy for educational purposes only and does not replace medical advice. Ask your healthcare team for a safe plan to stop drinking and for medication, thiamine, and device decisions tailored to you.
Get notified when new evidence is published on alcoholic cardiomyopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.